ACR Convergence 2021 Archives - Page 108 of 132

Abstract Number: 0272

RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease
Abstract Number: 0616

Race and Socioeconomic Status and COVID-19 Outcomes in Patients with Rheumatic Diseases: Findings from a Tertiary Care Center in the Deep South
Abstract Number: 0771

Race, Ethnicity and Patient-Reported Outcomes in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 0619

Racial and Ethnic Disparities in Pregnancy Outcomes Among Women with Rheumatic Diseases: A Systematic Literature Review and Quantitative Analysis
Abstract Number: 0329

Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort
Abstract Number: 1023

Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network
Abstract Number: 1264

Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
Abstract Number: 0492

Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Abstract Number: 0601

Racial Differences in Medication Beliefs Among SLE Patients
Abstract Number: 1780

Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis
Abstract Number: 0956

Racial Disparities in Renal Outcomes over Time Among Hospitalized Children with SLE and Effects of Hospital Minority Composition
Abstract Number: 0596

Racial Disparities in US Adults with Systemic Lupus Erythematosus: Prevalence, Quality of Life, Comorbidities and Healthcare Costs
Abstract Number: 1034

Racial/ethnic Differences in Lupus Pregnancy Outcomes over 1 Decade: A US National Study
Abstract Number: 0495

Racial/Ethnic Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study
Abstract Number: 0613

Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
Abstract Number: 0907

Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Abstract Number: 0342

RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis
Abstract Number: 1815

Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
Abstract Number: 0548

Rapamycin Blocks the Profibrotic Effects of Fli1 Downregulation in Scleroderma Myeloid Cells
Abstract Number: 0199

Rapid Improvement in Cystoid Macular Edema with High Dose Intravenous Methylprednisolone in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases
Abstract Number: 0337

Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Abstract Number: 0113

Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Abstract Number: 1243

Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry
Abstract Number: 1884

Real-life Data for the Use of Anti-TNF Treatment in DADA2
Abstract Number: 1818

Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 0129

Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S
Abstract Number: 0586

Recommended Fiber Intake, but Not Overall Dietary Quality, Is Associated with Reduced Risk of Rheumatoid Arthritis – Results from a Nested Case-control Study
Abstract Number: 0788

Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Abstract Number: 1826

Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
Abstract Number: 0231

Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool
Abstract Number: 1283

Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
Abstract Number: 1737

Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Abstract Number: 1427

Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Abstract Number: 1790

Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study
Abstract Number: 0850

Regression Methods for Modeling Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scores for Early Stage Knee Osteoarthritis
Abstract Number: 1584

Relation of Depressive Symptoms to Alterations in Conditioned Pain Modulation in Knee Osteoarthritis: The Multicenter Osteoarthritis Study (MOST)
Abstract Number: 1588

Relation of Foot and Ankle Pain to Worsening Knee Pain: The MOST Study
Abstract Number: 0220

Relation of Knee Extensor Power to Worsening Cartilage Damage in the Knee: The MOST Study
Abstract Number: 0980

Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
Abstract Number: 1660

Relationship Between Risk of New Onset Diabetes Mellitus and Exposure to Individual Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
Abstract Number: 1822

Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Abstract Number: 1807

Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)
Abstract Number: 0799

Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
Abstract Number: 0010

Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Abstract Number: 1365

Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis
Abstract Number: 0167

Reliability of a Novel Pediatric Joint-Specific Scoring System for the Elbow, Wrist and Finger Joints
Abstract Number: 0792

Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
Abstract Number: 0462

Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Abstract Number: 1137

REMS Technology for the Assessment of Bone Health in a Male Population
Abstract Number: 0875

Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Abstract Number: 0304

Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
Abstract Number: 0769

Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
Abstract Number: 1628

Reproductive Health Knowledge Gaps, Needs, and Barriers Identified by Pediatric Rheumatology Providers
Abstract Number: 1158

Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
Abstract Number: 0914

Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study
Abstract Number: 1615

Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis
Abstract Number: 0405

Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Abstract Number: 0554

Reverse Signaling Through PD-L1 Plays a Central Role in Extracellular Matrix Protein Secretion from Cutaneous Myofibroblasts in Systemic Sclerosis
Abstract Number: 1454

RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis
Abstract Number: 0115

Rheumatic Disease Management by Resilient Rheumatology Providers in COVID-19 Pandemic: A National Veterans Affairs Follow-up Survey Assessing Provider Practice and Views Since June 2020
Abstract Number: 1167

Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
Abstract Number: 0803

Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
Abstract Number: 0581

Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data
Abstract Number: 0015

Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules
Abstract Number: 0253

Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Abstract Number: 0438

Rheumatological Immune-Related Adverse Events of Immune Checkpoint Inhibitors Based on the FDA Adverse Event Reporting System
Abstract Number: 0740

Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
Abstract Number: 0612

Rheumatology Care for the Underserved in Central Texas
Abstract Number: 1190

Rheumatology Continuing Professional Development for Primary Care Providers: A Systematic Review
Abstract Number: 0145

Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care
Abstract Number: 0484

RheumMadness: Creating an Online Community of Inquiry
Abstract Number: 1673

Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Abstract Number: 0095

Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City
Abstract Number: 1525

Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Abstract Number: 0284

Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study
Abstract Number: 0989

Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users
Abstract Number: 0958

Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Abstract Number: 1291

Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
Abstract Number: 0285

Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Abstract Number: 1939

Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Abstract Number: 1915

Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Abstract Number: 1925

Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Abstract Number: 0204

Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics After Prophylactic Anti-viral Agents
Abstract Number: 0111

Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Abstract Number: 1833

Risk of Major Adverse Cardiovascular Events (MACE) with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Abstract Number: 1898

Risk of Major Adverse Cardiovascular Events in a Large Cohort of Patients with Acute Calcium Pyrophosphate Crystal Arthritis
Abstract Number: 1675

Risk of Malignancy in Patients Treated with Tofacitinib: Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Abstract Number: 1046

Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea
Abstract Number: 1136

Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts
Abstract Number: 1658

Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
Abstract Number: 1722

Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Abstract Number: 1359

Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Abstract Number: 1713

Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Abstract Number: 0505

Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Abstract Number: 0988

Risk Prediction Models for Incident Systemic Lupus Erythematosus Using Lifestyle/Environmental Risk Factors and a Genetic Risk Score
Abstract Number: 1391

Rituximab Is Superior to Placebo in Polymyalgia Rheumatica Patients: A Double Blind Randomized Controlled Proof of Principle Trial
Abstract Number: 0987

Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial
Abstract Number: 0964

Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases
Abstract Number: L21

Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial
Abstract Number: 0395

RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Abstract Number: 0323

Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
Abstract Number: 1507

Role of CD4+ T Cells in the Pathogenesis of RA: Immunization with Citrullinated T Cell Epitopes Is Sufficient to Induce Immunological and Clinical Manifestations of Arthritis in DR4-Transgenic Mice
Abstract Number: 0252

Role of Clinical and Laboratory Parameters in Differentiating Infection from Disease Flare in Febrile Patients of Systemic Juvenile Idiopathic Arthritis
Abstract Number: 1821

Role of Patient Organizations in Implementation of Recommended Non-pharmacological Treatment Modalities in Spondyloarthritis: Evidence for the Effectiveness of Self-management Strategies
Abstract Number: 0994

Role of SLE Associated Cytokines in Generation of Mature Neutrophils
Abstract Number: 0527

Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Abstract Number: 1234

Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy
Abstract Number: 1078

Rural Veterans with Gout – “Rheum” for Improvement